debt_leverage_profile
Pre-revenue clinical-stage biotech; minimal debt, primarily equity-funded; near-zero leverage ratio, highly dilution-sensitive
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct rate sensitivity; no significant floating-rate debt, but higher rates raise cost of future equity/debt capital raises
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) API sourcing from China/India for peptide synthesis; 2) specialized adjuvant materials concentrated in EU/US single-source suppliers
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue; currency devaluation exposure effectively nil at current pre-commercial stage
Inferred
Agent_Inference
geographic_footprint
US-domiciled R&D operations; no international revenue markets; sovereign currency devaluation risk is negligible currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single-source CROs and CDMOs for antigen/adjuvant production; likely >30% operational input from 1-2 vendors
Inferred
Agent_Inference
business_model_type_primary
Cloud dependency is minimal; core operations are wet-lab and CRO-based; cloud termination would cause administrative disruption only
Inferred
Agent_Inference
business_model_type_secondary
Biotech R&D/licensing model; secondary potential via government/DoD grants and BARDA contracts for biodefense applications
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk; proprietary immunology platform reduces substitutability but CRO switching is feasible with 6-12 month delay
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is licensing/grants, not token or profit-sharing schemes; not a security offering
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low GDPR/CCPA exposure; primary data is preclinical/clinical trial data under FDA/IRB frameworks, not consumer personal data
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; small-cap niche biotech with no dominant market position in any therapeutic category
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional/grant-based at current stage; no recurring subscription revenue; milestone and licensing payments are episodic
Inferred
Agent_Inference
monetization_vector
Licensing deals, government grants (BARDA/NIH), and potential co-development partnerships; no commercial product sales yet
Inferred
Agent_Inference
pricing_architecture
Licensing royalties and milestone-based pricing; pricing power determined by clinical data strength and competitive IP moat
Inferred
Agent_Inference
pricing_power_rating
Moderate-low currently; pricing leverage increases substantially upon Phase 2/3 clinical proof-of-concept data readouts
Inferred
Agent_Inference
target_gross_margin_bracket
Biotech licensing at scale targets 80-90% gross margin; current stage shows negative margins due to R&D burn
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage risk; proprietary peptide-antigen IP is patent-protected; unauthorized use is enforceable infringement
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear at scale; licensing model allows revenue multiplication without proportional headcount growth via CRO outsourcing
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of incremental licensing revenue approaches near-zero once platform IP is established and validated clinically
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company operates no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC remains low via BD partnerships; key constraint is clinical validation cost, not customer acquisition spend
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value is platform-IP driven, not user-network driven; competitive moat is scientific, not viral
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk is low-moderate; AI aids target identification but cannot replace wet-lab immunogenicity validation processes
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; government biodefense grants (BARDA) provide recession-resistant funding; commercial pharma partnerships more cyclical
Inferred
Agent_Inference
customer_segment_primary
US government/DoD biodefense agencies (BARDA, NIH, DTRA) as primary grant and contract customers
Inferred
Agent_Inference
customer_segment_secondary
Mid-to-large pharmaceutical and biotech companies seeking co-development or licensing of peptide-based vaccine/therapeutic platforms
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated toward clinical-stage advancement; minimal legacy infrastructure; outsourced manufacturing keeps capex low, R&D-forward
Inferred
Agent_Inference
sec_cik
0002079272
High
SEC-EDGAR
ticker
LABT
High
SEC-EDGAR